The objectives of the Developmental Projects Program are to ensure a continual renewal of high-quality scientific endeavors in the DF/HCC Prostate Cancer SPORE and to fund efforts that will complement or enhance the overall quality of the DF/HCC Prostate Cancer SPORE. In general, the Developmental Projects Program has funded established investigators. Based on our review, we will be mindful of including more junior investigators. This Program will rely on the infrastructure created by the Administrative, Evaluation, and Planning Core (Core A) to: 1. Solicit applications and/or identify novel prostate cancer research projects 2. Evaluate these projects for funding 3. Fund innovative developmental projects 4. Re-evaluate projects for possible transition into full project status 5. Evaluate the success of the program

Public Health Relevance

The Developmental Research Program of the DF/HCC Prostate Cancel- Program is intended to attract established investigators to the field of prostate cancer in order to develop new ideas of investigation which may change the field or be developed into full projects in the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090381-13
Application #
8896744
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
2016-06-30
Budget Start
2015-07-01
Budget End
2016-06-30
Support Year
13
Fiscal Year
2015
Total Cost
$170,823
Indirect Cost
$81,230
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Graff, Rebecca E; Ahearn, Thomas U; Pettersson, Andreas et al. (2018) Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev 27:193-200
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Dickerman, Barbra A; Torfadottir, Johanna E; Valdimarsdottir, Unnur A et al. (2018) Midlife metabolic factors and prostate cancer risk in later life. Int J Cancer 142:1166-1173
McKay, Rana R; Werner, Lillian; Jacobus, Susanna J et al. (2018) A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castration-resistant prostate cancer. Cancer :
Larimer, Benjamin M; Bloch, Emily G; Nesti, Sarah et al. (2018) The Effectiveness of Checkpoint Inhibitor Combinations and Administration Timing Can Be Measured by Granzyme B PET Imaging. Clin Cancer Res :
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Chen, Sen; Cai, Changmeng; Sowalsky, Adam G et al. (2018) BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer. Cancer Res 78:5203-5215
Pakula, Hubert; Linn, Douglas E; Schmidt, Daniel R et al. (2018) Protocols for Studies on TMPRSS2/ERG in Prostate Cancer. Methods Mol Biol 1786:131-151
Elfandy, Habiba; Armenia, Joshua; Pederzoli, Filippo et al. (2018) Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. Mol Cancer Res :
Han, W; Gao, S; Barrett, D et al. (2018) Reactivation of androgen receptor-regulated lipid biosynthesis drives the progression of castration-resistant prostate cancer. Oncogene 37:710-721

Showing the most recent 10 out of 261 publications